CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis
upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and
cGMP pathway.
The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and
renal dysfunction will improve renal function with increased sodium excretion, glomerular
filtration rate and effective renal plasma flow and renal function reserve as compared to the
response of placebo-treated subjects.